AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03004612 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Linagliptin + metformin
Description: Linagliptin-Metformin 2.5/850mg twice daily plus a lifestyle modification program based on nutritional assesment, physical activity prescription and general counseling
Study NCT03004612 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin 850mg twice daily plus a lifestyle modification program based on nutritional assesment, physical activity prescription and general counseling
Study NCT00681135 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sonic toothbrush (Philips Sonicare® FlexCare, Typ HX6942/04)
Description: toothbrushing with a sonic toothbrush and sealant coating (ProSeal™) of the enemal surface around the brackets
Study NCT00681135 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: manual toothbrush / interdental toothbrush (elmex® Inter X medium toothbrush / interdental brush Curaprox®)
Description: toothbrushing with a manual toothbrush and interdental brush and sealant coating (ProSeal™) of the enemal surface around the brackets
Study NCT00681135 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: manual toothbrush (elmex® Inter X medium toothbrush)
Description: toothbrushing with a manual toothbrush and sealant coating (ProSeal™) of the enemal surface around the brackets
Study NCT00681135 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: manual toothbrush (elmex® Inter X medium toothbrush)
Description: toothbrushing with a manual toothbrush without sealant coating of the enemal surface around the brackets
Study NCT04124302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glulisine
Description: A kind of bolus insulin will be insulin glulisine if participant used insulin glulisine before entering the trial.
Study NCT04124302 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glulisine
Description: A kind of bolus insulin will be insulin glulisine if participant used insulin glulisine before entering the trial.
Study NCT04124302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Aspart
Description: A kind of bolus insulin will be insulin aspart if participant used insulin aspart before entering the trial.
Study NCT02845921 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: leg elevation
Description: A stand making an angle of 30 degree to the horizontal is used to elevate both the legs
Study NCT02845921 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: leg wrapping
Description: Esmarch bandage is used to wrap each lower limb
Study NCT02845921 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: no intervention has been done
Study NCT00424476 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo IV plus standard therapy; placebo administered on Days 0, 14, 28, and every 28 days thereafter through Week 48.
Study NCT00424476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belimumab 1 mg/kg
Description: Belimumab 1 mg/kg IV plus standard therapy on Days 0, 14, 28, and every 28 days thereafter through Week 48.
Study NCT00424476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belimumab 10 mg/kg
Description: Belimumab 10 mg/kg IV plus standard therapy on Days 0, 14, 28, and every 28 days thereafter through Week 48.
Study NCT04124302 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Aspart
Description: A kind of bolus insulin will be insulin aspart if participant used insulin aspart before entering the trial.
Study NCT04124302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Lispro
Description: A kind of bolus insulin will be insulin lispro if participant used insulin lispro before entering the trial.
Study NCT06285578 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics supplementation
Description: Probiotics, Lactiplantibacillus plantarum TWK10, are packaged in powder form. Each participant consume one packet every day on a fasting status for 8 weeks.
Study NCT01454726 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: drug
Description: the Western medical treatment alone.
Study NCT04124302 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro
Description: A kind of bolus insulin will be insulin lispro if participant used insulin lispro before entering the trial.
Study NCT02721043 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peptides
Description: Each subject will receive ten (10) total doses of PGV001. PGV001 will be administered on study visit: v4, v6, v8, v10, v12, v14, v16, v18, v20 and v22.
Study NCT02721043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poly-ICLC
Description: Each subject will receive ten additional (10) total doses of the Poly-ICLC. The additional Poly-ICLC dose will be administered on study visit: v5, v7, v9, v11, v13, v15, v17, v19, v21 and v23.
Study NCT02721043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 10mg once daily oral dose for maintenance therapy in multiple myeloma patients.
Study NCT05144919 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Promotion of a biodiverse diet
Description: Component 1 - Participatory Identification of Intervention Approach (PIIA) Component 2. Local stakeholder consultation Component 3. Sensitisation of community Diversity club will receive capacity building from a Village health worker based on the prioritised species selected in component 2.~The following topics will be covered for each species selected for promotion:~1. Where to locally source inputs and expected price~2. How/when to prepare plots using organic inputs~3. Planting and best-practice management practices~4. Seed saving and storage~5. Possible intercropping combinations OR ecosystem services provided Component 4. Active Cooking demonstrations and Nutrition Education and counselling: Diversified cooking practices
Study NCT01982539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zipsor®
Description: Administration of Zipsor® (liquid filled capsules) to patients with mild to moderate acute pain: 25 mg/every 6 hours/up to 4 days treament. Drug taken by mouth.
Study NCT03825887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalbuphine
Description: Nalbuphine (Group B): Patients will be started on the same dose of 10 mcg / kg / hour as a background and 10mcg bolus dose with lock-out 20 minutes having the maximum allowed dose up to 40mcg /kg/ hour.~Any patient will continue to complain of pain rating 4-6 on VAS after reaching the maximum designated dose (which is 40 mcg/kg/hour) will be transferred to the ICU for close monitoring according to the internal hospital guidelines and getting him/her out of the study.~There is no drug shifting at any part of the study.
Study NCT03825887 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: morphine (Group A): Patients will be started on the same dose of 10 mcg / kg / hour as a background and 10mcg bolus dose with lock-out 20 minutes having the maximum allowed dose up to 40mcg /kg/ hour.~Any patient will continue to complain of pain rating 4-6 on VAS after reaching the maximum designated dose (which is 40 mcg/kg/hour) will be transferred to the ICU for close monitoring according to the internal hospital guidelines and getting him/her out of the study.~There is no drug shifting at any part of the study.
Study NCT06285578 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIIT training
Description: HIIT training is conduct at the intensity of 85-90% VO2max for 2 minutes with 1-minute inactive resting interval, repeating for 7 times. 3 sessions per week for 8 weeks.
Study NCT01350271 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mebendazole polymorph A and C 500 mg
Description: Mebendazole tablets produced by the State Pharmaceutical Manufacturing Corporation of Sri Lanka, containing 500mg of mebendazole as a 50:50 mixture of Polymorphs A and C
Study NCT01350271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mebendazole polymorph C
Description: Mebendazole tablets manufactured by the State Pharmaceutical Manufacturing Corporation of Sri Lanka, containing 500mg dose of mebendazole as Polymorph C alone
Study NCT01350271 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets produced by the State Pharmaceutical Manufacturing Corporation of Sri Lanka
Study NCT03224312 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study NCT01116063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled iloprost
Description: Inhalation Initial: 2.5 mcg/dose; if tolerated, increase to 5 mcg/dose; administer 6 times daily
Study NCT04386850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral 25-Hydroxyvitamin D3
Description: Subjects in the case group will receive 25 mcg of 25(OH)D3 once daily at bedtime for 2 months and the control group will receive placebo daily for 2 months.
Study NCT02890602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa
Description: Darbepoietin alfa will be administered subcutaneously at a fixed dose of 360㎍. If it is impossible, administration by intravenous infusion is okay.
Study NCT02870153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOX
Description: Oxaliplatin 130mg/m2 IV on D1 every 21 days and S-1 80mg/m2/day PO \[BSA \<1.25 40mg bid (total 80mg/day); BSA ≥1.25 - \<1.5 50mg bid (total 100mg/day); BSA ≥1.5 60mg bid (total 120mg/day)\], divided by two on D1-14 every 21 days
Study NCT02870153 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: XELOX
Description: Oxaliplatin 130mg/m2 IV on D1 every 21 days and Capecitabine 2000mg/m2/day PO, divided by two on D1-14 every 21 days
Study NCT04390243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: Given PO
Study NCT01312948 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prototype mask (known as Pixi)
Description: This is a prototype mask to be used with continuous positive airway pressure (CPAP) or non-invasive ventilation (NIV) therapy. The mask attaches to the face, covering the nose, and is kept in place with headgear. Therapy is delivered through the mask via a tube which attaches to the CPAP or NIV device.
Study NCT04390243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib
Description: Given PO
Study NCT01166126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temsirolimus
Description: Given IV
Study NCT01166126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: selumetinib
Description: Given orally
Study NCT01166126 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02087865 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: donepezil HCL
Study NCT02087865 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01928810 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioural Therapy
Description: 12 sessions of CBT including psychoeducation, interoceptive exposure and in-vivo exposure
Study NCT01928810 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy
Description: 12 sessions of CBT including psychoeducation, interoceptive exposure and in-vivo exposure
Study NCT06285578 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo supplementation
Description: Yeast powder replaces probiotics in each packet. Each participant consume one packet every day on a fasting status for 8 weeks.
Study NCT06285578 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo supplementation
Description: Yeast powder replaces probiotics in each packet. Each participant consume one packet every day on a fasting status for 8 weeks.
Study NCT03324048 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: relaxation session
Description: During relaxation session, patients anxious will have three electrodes for save heart rate variability and a sensor for save value of the partial pressure of carbon dioxide.~Before and after relaxation session, patient evaluates his anxiety by visual analogue scale (VAS) and State-Trait Anxiety Inventory (STAI-Y).
Study NCT02854657 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Skin Self- examination structured training
Description: A PowerPoint presentation will be provided as a PDF file. The file will be available in English and Spanish. This is the same skin self-examination structured training intervention used in the original RCT (MoleScore)
Study NCT02854657 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Skin Self- examination structured training
Description: A PowerPoint presentation will be provided as a PDF file. The file will be available in English and Spanish. This is the same skin self-examination structured training intervention used in the original RCT (MoleScore)
Study NCT02854657 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Skin Self- examination structured training
Description: A PowerPoint presentation will be provided as a PDF file. The file will be available in English and Spanish. This is the same skin self-examination structured training intervention used in the original RCT (MoleScore)
Study NCT05802498 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IRMA
Description: For patients in an advanced state of illness, advanced neuromotor rehabilitation treatment included 1) robot therapies, 2) specific water courses (e.g. walking pools, hydrokinesiotherapy pools, etc.), 3) advanced cognitive treatments (e.g. virtual reality courses); 4) augmentative immersive therapy in a virtual environment; 5) courses also dedicated to social reintegration and inclusive activities (theatre-therapy, art-therapy, dance-therapy, agro-therapy, etc.).
Study NCT03463122 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: field of regard-focused visual exploration therapy
Description: field of regard-focused visual exploration therapy in addition to conventional therapy
Study NCT03463122 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: conventional therapy
Description: conventional therapy for stroke rehabilitation
Study NCT06337045 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Complex prevention and rehabilitation intervention
Description: The complex intervention started and ended with individual consultations with health professionals and furthermore included physical exercise, smoking cessation, alcohol treatment, dietary interventions, AF specific patient education, MediYoga, and/or psychosocial support.
Study NCT02442102 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise and sensory stimulation
Description: 60-minute sessions with sensory electrical stimulation (SES) applied 5 days per week with oromotor exercises completed when patient is able to participate
Study NCT04239976 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FitBit
Description: Wear FitBit for gait assessment test
Study NCT01797068 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Navigator
Description: Patients in the intervention group will be offered patient navigation and timely access to comprehensive care and services through Project Access-New Haven (PA-NH), a local non-profit organization that coordinates the provision of donated medical care and services to underserved patients through a network of participating hospitals and volunteer physicians.
Study NCT01797068 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Patients in the standard of care group will experience the usual intake process in the ED setting.
Study NCT01233349 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Litramine
Description: 2 tablets 3 times daily (oral consumption, 30 minutes after meal)
Study NCT01233349 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 tablets 3 times daily (oral consumption, 30 minutes after meal)
Study NCT03174457 — intervention group
Intervention type: DRUG
Intervention: Micafungin
Description: Intravenous
Study NCT01636011 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative Medicine Treatment
Description: Osteopathic Manipulative Medicine Treatment
Study NCT01636011 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Light Touch sham
Description: Light Touch sham
Study NCT01298362 — intervention group
Intervention type: DRUG
Intervention: Aromatase Inhibitors
Study NCT01298362 — intervention group
Intervention type: DRUG
Intervention: Chemotherapy
Study NCT00070070 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TICE®-strain BCG
Study NCT00070070 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NY-ESO-1 protein
Study NCT00070070 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Study NCT02726516 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PRJ-205
Description: 1 sachet per day
Study NCT02726516 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 sachet per day
Study NCT03563729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab Injection [Keytruda]
Description: Alone
Study NCT03563729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab Injection [Yervoy]
Description: In combination with nivolumab.
Study NCT03563729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab Injection [Opdivo]
Description: In combination with ipilimumab.
Study NCT03563729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib
Description: In combination with binimetinib
Study NCT03563729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: In combination with encorafenib
Study NCT03563729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: In combination with dabrafenib
Study NCT03563729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: In combination with trametinib
Study NCT02064400 — intervention group
Intervention type: OTHER
Intervention: Musculoskeletal Ultrasound
Description: 7-joint musculoskeletal ultrasound scan
Study NCT02064400 — intervention group
Intervention type: OTHER
Intervention: Semi-structured patient interview
Description: Semi-structured patient interview
Study NCT00219349 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: 14 weekly sessions of individualized CBT
Study NCT00219349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: escitalopram
Description: 10-20 mg per day for 12 weeks
Study NCT00604760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEM 3454
Description: Capsule 5 mg once a day
Study NCT00604760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEM 3454
Description: Capsule 15 mg once a day
Study NCT00604760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEM 3454
Description: Capsule 50 mg once a day
Study NCT00604760 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for MEM 3454
Description: Capsule once a day
Study NCT04130477 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tunnel attachments and light Nickel Titanium wire
Description: Tunnel attachments planned virtually and light Nickel Titanium wire
Study NCT04130477 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Clear Aligner therapy
Description: Clear Aligner therapy
Study NCT04525066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid
Description: Patients in the treatment group received hyaluronic acid injection into the unaffected vocal cord intra-operatively during transoral laser microsurgery for early glottic cancer.
Study NCT04525066 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No Hyaluronic Acid Injection Injection
Description: Patients in the placebo group did not receive hyaluronic acid injection into the unaffected vocal cord intra-operatively during transoral laser microsurgery for early glottic cancer.
Study NCT01389856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosentan
Description: 2 mg/kg of weight at birth twice daily (b.i.d); quadrisectable 32 mg tablet of bosentan dispersed in sterile water and administered by nasogastric or orogastric tube.
Study NCT01389856 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: twice daily (b.i.d); quadrisectable 32 mg tablet of matching placebo dispersed in sterile water and administered by nasogastric or orogastric tube.
Study NCT00731640 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ReSTOR
Description: AcrySof ReSTOR +4 Intraocular Lens (IOL) unilaterally implanted
Study NCT02221674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol
Study NCT04104607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-1, PSMAxCD3
Description: Infusion of CC-1 over 24 hours for 7 days with possible intra-patient dose-escalation
Study NCT02484209 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin 1500 mg daily for 16 weeks
Study NCT02484209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride
Description: glimepiride 2-4 mg twice daily for 16 weeks